Benzinga | Apr 26, 2021 08:03AM EDT

BioCardia Signs Agreement With Leading Japanese Biotechnology Company For Catheter Biotherapeutic Delivery Product Candidates; Co. To Receive $500K

BioCardia(r), Inc. (NASDAQ:BCDA), today announced that it has entered into an agreement with a leading Japanese biotechnology company related to BioCardia Helix catheter biotherapeutic delivery product candidates. Under the terms of the agreement, BioCardia will receive $500,000, a portion of which is creditable for biotherapeutic delivery products and support services. The agreement has a one-year term with an option to negotiate for a non-exclusive world-wide license to BioCardia Helix catheter biotherapeutic delivery product candidates for certain cell types for cardiac indications.